total
number
subject
recruit
particip
studi
subject
nonsmok
year
studi
popul
consist
three
group
patient
mild
asthma
patient
sever
asthma
control
tabl
diagnosi
asthma
base
gina
guidelin
asthma
sever
defin
base
sever
asthma
consensu
patient
select
among
outpati
visit
academ
medic
centr
amsterdam
wherea
control
recruit
advertis
hospit
premis
mild
asthma
group
compos
nonsmok
patient
episod
chest
symptom
prebronchodil
predict
document
revers
ml
inhal
salbutamol
andor
airway
hyperrespons
mgml
methacholin
bromid
past
month
patient
treat
low
dose
inhal
corticosteroid
inhal
beclomethason
equival
andor
bronchodil
sever
asthma
group
consist
nonsmok
patient
episod
chest
symptom
revers
ml
andor
document
hyperrespons
methacholin
mgml
past
year
use
corticosteroid
inhal
beclomethason
equival
oral
corticosteroid
bronchodil
month
one
sever
asthma
exacerb
requir
oral
steroid
burst
past
month
control
group
compos
subject
neg
histori
chest
symptom
prebronchodil
predict
document
absenc
airway
hyperrespons
mgml
time
studi
patient
asthma
clinic
stabl
loss
control
acut
asthma
exacerb
defin
recent
american
thorac
societyeuropean
respiratori
societi
atser
recommend
evid
chest
infect
past
week
academ
medic
centr
ethic
committe
amsterdam
nl
usa
grant
ethic
approv
studi
particip
gave
written
inform
consent
studi
three
group
prospect
design
three
visit
week
screen
phase
medic
histori
asthma
control
questionnair
acq
physic
examin
standard
spirometri
postbronchodil
spirometri
andor
methacholin
challeng
perform
two
separ
day
baselin
ebc
nasopharyng
flock
swab
throat
flock
swab
induc
sputum
expir
air
obtain
subject
patient
control
repeat
procedur
week
studi
perform
month
august
march
sampl
use
multiplex
pcr
analysi
visit
subject
contact
twice
phone
assess
asthma
control
acq
inquir
symptom
intercurr
respiratori
tract
infect
case
latter
upcom
visit
postpon
week
sputum
induct
perform
accord
er
recommend
short
patient
receiv
pretreat
inhal
salbutamol
measur
standard
spirometri
three
episod
inhal
aerosol
hyperton
salin
solut
gener
ultrason
nebul
klavam
bielefeld
germani
safeti
reason
sever
asthma
patient
sputum
induc
accord
valid
algorithm
start
isoton
salin
prior
sputum
product
subject
ask
rins
mouth
water
swallow
blow
nose
minim
contamin
sputum
saliva
postnas
drip
fluid
whole
sputum
sampl
process
accord
valid
protocol
equal
volum
dithiotreitol
mm
dtt
mm
tri
buffer
ph
ad
sputum
dtt
sigma
chemic
compani
st
loui
mo
usa
sampl
incub
shake
bath
min
period
gentl
manual
mix
ensur
complet
homogen
cell
number
count
count
chamber
slide
stain
romanovski
dade
behr
switzerland
supernat
store
analysi
multiplex
viral
pcr
sputum
sampl
contain
nonsquam
cell
viabl
cell
exclud
analysi
exhal
breath
condens
collect
ecoscreen
erich
jaeger
gmbh
hochberg
germani
accord
er
recommend
patient
breath
nonrebreath
valv
separ
inhal
exhal
air
wear
nose
clip
promot
gener
aerosol
lower
airway
patient
ask
perform
three
forc
expiratori
reserv
volum
erv
manoeuvr
residu
volum
directli
mouthpiec
condens
frozen
temperatur
min
tidal
breath
sampl
tube
remov
cool
system
condens
probe
thaw
pour
polyethylen
storag
tube
expend
hamburg
germani
ebc
store
patient
ask
perform
two
forc
expir
erv
manoeuvr
residu
volum
expiratori
tube
contain
gelatin
filter
aerosol
captur
sartoriu
germani
gelatin
filter
dissolv
magnapur
lysi
solut
ml
total
nucleic
acid
extract
kit
roch
penzberg
germani
store
nasal
throat
swab
chosen
upper
airway
assess
nasopharyng
collect
flexibl
twist
plastic
swab
copan
italia
brescia
itali
pass
nostril
resist
posterior
nasopharynx
encount
throat
collect
soft
swab
pass
mouth
rub
tonsil
posterior
pharynx
swab
place
viral
transport
media
sampl
kept
process
sampl
nasal
swab
throat
swab
induc
sputum
gelatin
filter
ebc
test
intern
control
multiplex
pcr
assay
respiratori
virus
adenoviru
enteroviru
influenza
viru
b
rhinoviru
hrv
respiratori
syncyti
viru
rsv
metapneumoviru
mpv
parechoviru
parainfluenza
coronaviru
human
bocaviru
hbov
multiplex
pcr
perform
essenti
describ
total
nucleic
acid
isol
magna
pure
lc
roch
briefli
sampl
isol
use
total
nucleic
acid
extract
kit
roch
purifi
nucleic
acid
elut
elut
buffer
subsequ
cdna
gener
essenti
describ
previous
final
revers
transcript
reaction
contain
ng
random
hexam
buffer
mm
ph
mm
kcl
triton
mm
u
superscript
ii
invitrogen
paisley
uk
dntp
u
rnasin
na
eluat
subsequ
mixtur
incub
min
multiplex
pcr
perform
roch
roch
typic
reaction
contain
probe
master
roch
nm
primer
nm
probe
cdna
total
volum
cycl
condit
follow
min
min
follow
cycl
consist
min
data
analys
use
softwar
roch
colour
compens
object
creat
describ
manual
posit
control
viru
includ
run
well
neg
control
statist
analysi
perform
use
spss
softwar
version
window
spss
inc
chicago
il
usa
normal
distribut
examin
use
test
baselin
characterist
group
compar
use
unpair
combin
correct
multipl
comparison
bonferroni
differ
frequenc
posit
viru
identif
analys
use
crosstab
test
current
sampl
size
subject
per
group
allow
detect
differ
posit
viral
detect
rate
group
statist
power
microbiolog
find
three
visit
mild
asthma
sever
asthma
control
shown
fig
among
respiratori
virus
examin
hrv
adenoviru
rsv
parainfluenza
hbov
influenza
b
coronaviru
detect
contrast
sampl
neg
enteroviru
influenza
mpv
parechoviru
parainfluenza
even
though
control
show
lowest
viral
detect
rate
three
visit
differ
total
number
posit
sampl
p
fig
total
viru
identif
differ
sampl
techniqu
shown
tabl
highest
viral
detect
rate
came
sampl
obtain
induc
sputum
throat
swab
wherea
expir
air
ebc
nasal
swab
three
sampl
techniqu
yield
least
posit
sampl
howev
fraction
posit
sampl
significantli
differ
five
sampl
method
p
identifi
virus
consist
induc
sputum
throat
swab
among
posit
case
shown
fig
viru
distribut
show
larg
variabl
week
rsv
detect
one
visit
wherea
adenoviru
rhinoviru
hbov
detect
patient
popul
three
visit
howev
none
patient
show
evid
persist
infect
viru
fig
studi
show
repeat
lumin
sampl
airway
identifi
presenc
respiratori
virus
patient
clinic
stabl
asthma
well
healthi
control
adenoviru
rhinoviru
rsv
piv
influenza
b
viru
coronaviru
hbov
identifi
wherea
enteroviru
influenza
mpv
parechoviru
parainfluenza
remain
undetect
notabl
posit
viral
identif
rate
significantli
differ
patient
mild
sever
asthma
healthi
control
infect
persist
period
find
suggest
clinic
stabl
asthma
character
elev
persist
viral
presenc
intralumin
airway
knowledg
first
studi
address
longitudin
persist
viral
presenc
asthma
repeat
sampl
nasopharynx
induc
sputum
exhal
air
use
pentaplex
pcr
respiratori
virus
result
extend
find
harju
et
al
observ
signific
differ
presenc
four
respiratori
virus
rhinoviru
enteroviru
rsv
adenoviru
induc
sputum
clinic
stabl
asthmat
control
nevertheless
examin
bronchial
tissu
report
rhinoviru
frequent
detect
clinic
stabl
asthmat
compar
control
discrep
may
attribut
differ
viral
presenc
airway
tissu
intralumin
sampl
latter
support
recent
studi
examin
respiratori
virus
bronchoalveolar
lavag
also
show
similar
detect
rate
asymptomat
asthmat
children
control
taken
togeth
present
data
suggest
respiratori
virus
preval
intralumin
airway
asthmat
compar
control
current
observ
overal
viral
detect
rate
consider
lower
rate
report
invas
techniqu
bronchoalveolar
lavag
bronchial
biopsi
howev
collect
examin
sampl
techniqu
subject
asthmat
show
viru
posit
given
visit
henc
differ
detect
rate
studi
like
technic
tempor
andor
biolog
factor
invas
method
sampl
differ
locat
respiratori
tract
viral
presenc
may
differ
region
sampl
noninvas
method
although
studi
conclud
nasal
wash
slightli
sensit
viral
detect
swab
other
report
sensit
equal
adult
chose
latter
nasal
swab
easier
carri
nasal
wash
caus
less
discomfort
observ
particularli
low
detect
rate
expir
air
ebc
unexpect
even
though
sampl
rate
differ
significantli
five
techniqu
present
studi
result
suggest
induc
sputum
may
repres
better
option
respect
fit
previou
studi
use
induc
sputum
viral
detect
suggest
discrep
upper
intrapulmonari
airway
sampl
regard
detect
respiratori
virus
asthma
control
made
larg
effort
adequ
select
subject
use
optim
methodolog
first
patient
care
select
base
latest
asthma
guidelin
top
ad
object
criteria
confirm
exclud
variabl
airway
obstruct
patient
control
respect
furthermor
distinct
mild
sever
asthma
base
object
quantit
criteria
includ
medic
usag
care
exclud
patient
symptom
respiratori
infect
past
week
time
may
total
exclud
possibl
recent
viral
ill
experiment
infect
shown
virus
occasion
persist
lower
airway
week
final
exclud
medic
bia
particularli
regard
dose
inhal
steroid
group
howev
differ
inevit
select
mild
sever
asthma
second
microbiolog
find
obtain
pentaplex
pcr
abl
yield
result
qualit
manner
pentaplex
approach
increasingli
appli
routin
practic
molecular
diagnost
respiratori
virus
show
almost
complet
concord
multiplex
pcr
correspond
pcr
although
cross
point
cp
valu
could
give
indic
high
low
viral
load
assay
essenti
qualit
allow
statement
replic
properti
viru
airway
asthmat
patient
healthi
control
implicit
limit
approach
test
presenc
nonvir
respiratori
pathogen
link
persist
sever
asthma
beyond
object
present
studi
final
current
sampl
size
provid
power
detect
differ
group
reason
clinic
pathophysiolog
relev
could
obtain
differ
viral
detect
rate
group
accept
differ
subject
per
group
rather
expand
sampl
size
therebi
increas
statist
power
chose
sampl
subject
three
subsequ
time
point
therefor
present
sampl
size
suffic
detect
smaller
differ
viru
detect
rate
group
taken
account
design
futur
studi
result
interpret
regardless
sampl
techniqu
use
present
studi
appear
identif
virus
airway
patient
clinic
stabl
asthma
exceed
normal
control
neither
differ
sever
mild
asthma
suggest
inflamm
andor
impair
innat
immun
defenc
enhanc
viral
presenc
airway
asthma
howev
use
sampl
window
exclud
possibl
cytokin
profil
airway
inflamm
asthma
may
still
imped
viral
clearanc
asthma
nevertheless
none
sampl
show
consist
presenc
virus
individu
subject
week
variabl
viru
strain
time
extend
previou
find
infant
illustr
seri
infect
rather
persist
infect
occur
asthmat
healthi
adult
taken
togeth
find
argu
hypothesi
mainten
sever
asthma
driven
persist
viru
infect
actual
virus
detect
studi
clinic
interest
obvious
viral
spectrum
influenc
season
variat
nevertheless
detect
bocaviru
surpris
report
mainli
paediatr
patient
respiratori
diseas
rare
adult
may
suggest
link
host
characterist
medic
usag
presenc
bocaviru
viru
airway
asthmat
need
confirm
larger
prospect
studi
asthmat
control
furthermor
exclud
presenc
atopi
without
exposur
relev
allergen
may
affect
result
howev
question
beyond
scope
present
studi
final
exclud
microb
respiratori
virus
influenc
mainten
cours
asthma
recent
studi
base
cultur
independ
pcr
techniqu
provid
evid
suggest
differenti
bacteri
presenc
bronchial
brush
bronchoalveolar
lavag
clinic
stabl
asthmat
control
conclus
present
studi
show
patient
clinic
stabl
asthma
healthi
control
similar
detect
rate
respiratori
virus
sampl
nasopharynx
sputum
exhal
air
data
indic
viral
presenc
airway
stabl
asthmat
vari
time
rather
persist
find
suggest
mainten
chronic
asthma
link
persist
viral
presenc
airway
vt
pj
conceiv
design
studi
draft
manuscript
vt
execut
clinic
part
studi
js
rm
rl
execut
laboratori
part
studi
mpf
gec
particip
concept
design
studi
ehb
involv
draft
manuscript
author
read
approv
final
manuscript
prior
submiss
author
declar
compet
interest
